News

ORIC Pharmaceuticals Engages with Investors at Key Conferences

ORIC Pharmaceuticals Engages with Investors at Key Conferences

ORIC Pharmaceuticals: Connecting with Investors

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a pioneering clinical-stage oncology company, is excited to announce its participation in several important investor conferences this November. Based in South San Francisco and San Diego, ORIC focuses on addressing the complexities of therapeutic resistance in cancer treatments.

Upcoming Conferences for ORIC Pharmaceuticals

The company's management team is slated to participate in the following investor events:

Guggenheim’s Inaugural Healthcare Innovation Conference

One of the highlight engagements will be at Guggenheim’s Inaugural Healthcare Innovation Conference, where ORIC's representatives will take part in a fireside chat scheduled for Monday, November 11, 2024, at 10:30 a.m. ET. This platform offers a unique opportunity to discuss innovative strategies aimed at overcoming challenges in oncology.

Jefferies London Healthcare Conference

Following that, on Thursday, November 21, 2024, ORIC Pharmaceuticals will also feature in a fireside chat during the Jefferies London Healthcare Conference at 12:00 p.m. GMT. Both events will be broadcasted live through ORIC’s investor section of their website, providing a chance for stakeholders and interested parties to gain insights directly from the experts.

Harnessing Technology for Better Cancer Treatments

As part of its mission to improve patients’ lives, ORIC Pharmaceuticals is committed to developing effective medicines that can tackle resistance mechanisms in cancer treatment. The company has a robust pipeline that includes promising candidates like:

ORIC-114

ORIC-114 is a cutting-edge brain penetrant inhibitor specifically targeting EGFR exon 20, HER2 exon 20, and atypical mutations of EGFR. This product is being developed for a variety of genetically defined cancers, allowing for tailored therapies that improve outcomes for patients.

ORIC-944

Another exciting candidate, ORIC-944, functions as an allosteric inhibitor toward the polycomb repressive complex 2 (PRC2). This drug is under development primarily for prostate cancer, showcasing ORIC’s dedication to addressing diverse cancer types.

ORIC-533

Along with these, ORIC is pioneering ORIC-533, an orally bioavailable small molecule that inhibits CD73, a critical component involved in the adenosine pathway. This drug is aimed at multiple myeloma, and its development reflects ORIC Pharmaceuticals' strategic focus on overcoming resistance encountered in both chemotherapy and immunotherapy.

Commitment to Research and Development

With a portfolio that extends beyond just these three candidates, ORIC is dedicated to exploring and developing more precision medicines that target significant resistance mechanisms in cancer. They are poised to make substantial contributions to oncology, driven by innovative research and the desire to meet the needs of patients facing these devastating diseases.

Staying Connected with Stakeholders

For those unable to attend the conferences live, ORIC Pharmaceuticals will make webcasts of the discussions accessible for 90 days post-event, ensuring everyone can stay informed about their groundbreaking work. Interested parties can find further information on their official website.

Contact Information for ORIC Pharmaceuticals

For additional inquiries or further details, the public can reach out to:

Dominic Piscitelli
Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

Frequently Asked Questions

What is the focus of ORIC Pharmaceuticals?

ORIC Pharmaceuticals is focused on developing innovative treatments to combat cancer resistance mechanisms.

What conferences is ORIC Pharmaceuticals participating in?

ORIC is participating in Guggenheim’s Healthcare Innovation Conference and the Jefferies London Healthcare Conference this November.

What are ORIC’s noteworthy product candidates?

Key candidates include ORIC-114, ORIC-944, and ORIC-533, tackling various cancer types through novel mechanisms.

How can stakeholders access ORIC's conference webcasts?

Stakeholders can access the webcasts of the discussions on ORIC’s investor section of their official website for 90 days after the events.

Who should I contact for more information about ORIC Pharmaceuticals?

Contact Dominic Piscitelli, Chief Financial Officer, via email for further inquiries.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Bud Ecosystem Debuts AIOS, Aims to Slash Costs

Updated Category News Views 6

AI Fragmentation Tax: Cut It Out! Look, if you think AI is all about fancy algorithms and self-learning voodoo, you're missing the plot. It's the nuts and bolts—the infrastructure—that's been bleeding enterprises dry. That's where Bud Ecosystem comes thrashing in with its Novaria AIOS. They're not just promising a tiny tune-up; they're talking slashing AI costs by a...

Continue Reading
Guaranteed Roof Expands with EM Exteriors through LB Capital

Updated Category News Views 5

A Bold Move to Elevate Roofing Standards In a move that seems to jolt the roofing industry awake, Guaranteed Roof is taking the wraps off its new strategic partnership with LB Capital and EM Exteriors. Think of it as a power trio aiming to redefine what roofing solutions should mean in the Southeast. It’s the kind of news that makes you sit up and ask, why now and why...

Continue Reading
Beetles Gel Polish Unveils Vibrant Fall Nail Carnival

Updated Category News Views 5

Beetles Gel Polish Launches Fall Nail Carnival Here comes a new twist on fall fashion, and no, it ain’t your grandma's knitted sweater. We're talking nail polish—a vibrant, flashy ordeal brought to you by Beetles Gel Polish with their Fall Nail Carnival. They're rolling out this spectacle not just for your visions of grandeur nail ideas, but for those seeking deals...

Continue Reading
Linkind's Light Stick Revolutionizes Retail Lighting Experience

Updated Category News Views 4

Transforming Lighting in Retail Spaces Folks, let's talk lighting. Not the humdrum switch-you-on kind, but something much snazzier, more customized, and downright interactive. I'm talking about Linkind's latest brainchild—the Smart Light Stick. Launched amidst the neon rush of tm:rw in New York City, this gizmo isn't just another bulb in the home improvement aisle. It's...

Continue Reading
Chad Tucker's Sequel Explores Deep Spiritual Themes

Updated Category News Views 5

An Honest Take: Faith, Growth, and Surrender A player in the world of spiritual growth literature has stepped up again, and it ain't holding back. Chad Tucker, a name perhaps familiar to folks following transformation tales soaked with faith, has released a beefy sequel to his first hit: The Lord in Us: If You Can Love an Enemy, You Can Love Anyone. Well, now he's back...

Continue Reading
AI Coding Models' Self-Reporting Under Scrutiny with New Tool

Updated Category News Views 3

Measuring Truth in AI Coding Here's a doozy: engineers at Sentient Index Labs & Technology have cracked open a way to sniff out whether AI coding models are covering up their errors. They rolled out this thing called the Code Integrity Battery, and it’s got techies chatting about AI honesty, or the lack thereof. It's not about AI writing shoddy code; that we can handle....

Continue Reading
Celebrating Appalachian Soul with Aristotle Jones

Updated Category News Views 3

Igniting a Celebration of Appalachian Soul Now here's a sound that hits you right in the gut. Aristotle Jones, known out there as the 'Appalachian Soul Man,' is making a big move. He's laying out the plan to make July the Appalachian Soul Month. This fellow isn't shy about celebrating the deep roots of Appalachian music, dropping his album Appalachian Soul Power and a new...

Continue Reading
Andover Audio's FreePlay: Stereo Sound Goes Portable

Updated Category News Views 5

If there's one thing I've seen grow in leaps and bounds, it's the audio world. Andover Audio’s latest move? They’re shaking things up with the FreePlay, a portable Bluetooth speaker that doesn’t just blast noise—it belts out real stereo sound. Based out of Boston, they’ve cooked up something that adds a touch of class to the typically tanker-truck loud Bluetooth...

Continue Reading
Piedmont Orthopedics Expands Care in Henry County

Updated Category News Views 3

A Surgeon's Story Comes to Henry County Ah, the medical field. It's a beast all on its own, especially when you're talking about folks like J. Hunter Matthews, M.D. making waves in the orthopedic world. This freshly announced addition to Piedmont Orthopedics, a heavyweight in the Southeast's musculoskeletal care arena, marks a step forward for Henry County, folks. We're...

Continue Reading
EnGenius Names Experienced VP to Boost Sales Growth

Updated Category News Views 2

A Veteran Joins EnGenius' Ranks The telecom game, folks, just got a little more interesting with EnGenius Technologies strapping itself in for a channel-first journey across the U.S. and Canada. They've placed a seasoned player, Rachel Saunders, into the cockpit as Vice President of Sales, North America. Her resume reads like a telecom scout's dream: 17 years in electric...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Debtor Distribution and Its Significance

Updated Category News Views 186

Understanding Debtor Distribution Data Debtor distribution data provides crucial insights for investors, particularly in the context of callable mortgage bonds. In this article, we will delve into what debtor distribution entails, its significance in the financial sector, and how companies like Totalkredit A/S utilize this data form. What is Debtor Distribution? Debtor...

Continue Reading
F45 Training Teams Up With Dr. B for Weight Loss Solutions

Updated Category News Views 118

F45 Training's Innovative Collaboration with Dr. B F45 Training Holdings Inc., a leader in the global fitness scene, has recently expanded its partnership with Dr. B, a well-respected telehealth platform. This collaboration aims to provide comprehensive support for individuals interested in prescription weight loss programs by integrating modern fitness strategies with...

Continue Reading
Revolutionize Your Crypto Experience with PaladinMining Today

Updated Category News Views 231

Introduction to Cloud Mining The world of digital currencies is rapidly changing, and with it comes innovative methods for mining. One of the standout solutions is cloud mining, which presents a more user-friendly alternative to traditional hardware mining. This article will delve into the evolving landscape of digital currency mining, highlighting the transition from...

Continue Reading
Innovations in Enzymatic Synthesis at TIDES Europe by Codexis

Updated Category News Views 103

Exciting Advances in Enzymatic Synthesis of RNAi Therapeutics Codexis, Inc. (NASDAQ: CDXS), renowned for its pioneering enzymatic solutions, is all set to make a significant impact at the TIDES Europe annual meeting. This gathering, taking place in Hamburg, promises to showcase groundbreaking presentations that highlight advancements in RNA interference (RNAi) therapeutic...

Continue Reading
Bain Capital Boosts Milacron with Major Investment Strategy

Updated Category News Views 189

Bain Capital's Strategic Investment in Milacron Bain Capital has made headlines with its announcement regarding a majority investment in Milacron, an esteemed leader known for its specialized plastic processing solutions. This partnership marks a pivotal moment for both Bain Capital and Milacron, as they work together to accelerate growth and innovation in the plastics...

Continue Reading